Cancer cells

Contact

Group lead
Dr Rohini Sharma
+44 (0)20 3313 3059
r.sharma@imperial.ac.uk

Related themes

Disease areas

What we do

Primary liver cancer is the fourth most common cause of cancer-related death worldwide and unlike other cancer types, mortality rates continue to rise. Most liver cancers arise on a background of chronic liver disease secondary to viral infections, alcohol excess, fatty liver disease and other metabolic causes.  Our group is dedicated to the study of the mechanisms underlying the pathogenesis and molecular progression of liver cancer with the aim of providing novel diagnostic and therapeutic strategies. Since inception 10 years ago, the liver cancer group has published over 200 peer review papers, attracted significant grant funding and is a UK lead in clinical trials in liver cancer. 

Why it is important

Most liver cancers present at a late stage when treatment is essentially palliative. Even with the best medications, the response to treatment is approximately 20% and survival is rarely beyond 2 years. As the incidence of this cancer is increasing rapidly in our community, we want to find better ways of diagnosing liver cancer earlier so more people can be cured and to develop better therapeutics for those with advanced disease. 

How it can benefit patients

An improved molecular and clinical understanding of how liver cancer evolves is important to understand how novel therapies might be beneficial in the management of patients with HCC.

Summary of current research

  • Lipidomics as a biomarker of early liver cancer
  • Identification of novel biomarkers to predict the clinical course of disease
  • Evaluation of the role of innate and adaptive immunity as a prognostic marker and therapeutic target in liver cancer
  • Circulating free DNA as a novel biomarker for the diagnosis and therapeutic monitoring of liver cancer
  • Intratumor heterogeneity of primary and metastatic liver cancer
  • Identification and delineation of potential therapeutic targets
  • Application of radiomics to improve identification and prognostication in liver cancer

Connections

Funders and industry

Funders 
Industry
  • SIRTEX
  • Incyte pharmaceuticals
  • MSD
  • BMS
  • Boston Scientific
  • Roche
  • Esai
  • AAA
  • Astex Pharmaceuticals

For patients

For patient-related information please see:

PhD students

GE Healthcare worldwide

When we have funding for PhD studentships, we advertise them through central channels such as Find a PhD. Information is also available on the Surgery and Cancer study page. If no studentships are currently advertised, please get in touch with the group lead with proposed project titles to discuss further. 

Our current PhD students:

  • Jamie Beaumont
  • Jian Huang

Clinical trials

Active trials

  • JAKaL - A phase Ib study of INCB039110, a JAK1 inhibitor, in advanced hepatocellular carcinoma
  • PRIME - PRIME-HCC: Preliminary assessment of safety and bioactivity of the Ipilimumab and Nivolumab combination prior to liver resection (LR) in hepatocellular carcinoma (HCC).
  • ETAL - A Phase Ib Study of Pembrolizumab following Trans-Arterial Chemoembolization in Primary Liver Carcinoma MK3475-540
  • Precision HCC - Molecular markers to enable precision medicine in Hepatocellular Cancer
  • ArTisaN - A Phase II Assessment of the Safety and Efficacy of TheraSphere® Selective Internal Radiation Therapy (SIRT) in the treatment of Metastatic (Liver) Neuroendocrine Tumours (NETs).
  • ATB/Antibiotic ICPI - Qualification of antibiotic-induced gut perturbation as a therapeutically actionable driver of anti-cancer immunity.
  • On-Covid - OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic

Planned trials
  • Pelican (DP-IC001) - A phase II study of etoposide-carboplatin (EP) chemotherapy in combination with pembrolizumab and lenvatinib maintenance in advanced high-grade neuroendocrine tumours (HG-NETs).
  • STARKAP - Study fo TSR-042 in the treatment of HIV-associated combination antiretroviral therapy (cART) refractory kaposi Sarcoma
  • AdMuc-1 - Phase 1b Trial: Study of the toxicity and efficacy of a combination of Atezolizumab (Tecentriq), an anti-PD-L1 antibody, and the Ad-sig-hMUC-L 1/ecdCD40L vector vaccine for immunotherapy of patients with second line hepatocellular cancer (HCC).
  • Audit - Impact of COVID19 on clinical outcomes in hepatocellular carcinoma: A multicentre cohort study

 


Our researchers

Our researchers